vascular gtafts ישראל - עברית - Ministry of Health

vascular gtafts

גאמידה בע"מ - רופא - גרפטים ווסקולאריים

SAFE MICRO - NEONATAL OXYGENATOR SYSTEM ישראל - עברית - Ministry of Health

safe micro - neonatal oxygenator system

גאמידה בע"מ - צוות טכני - מחמצן ממברנה לתינוקות עד 6 ק'ג

זופרן זריקות 2 מגמל ישראל - עברית - Ministry of Health

זופרן זריקות 2 מגמל

novartis israel ltd - ondansetron as hydrochloride dihydrate - תמיסה להזרקה - ondansetron as hydrochloride dihydrate 2 mg/ml - ondansetron - ondansetron - adults:zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. zofran is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:zofran is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.

אונדנסטרון אינובמד להזרקה 2 מ"ג/מ"ל ישראל - עברית - Ministry of Health

אונדנסטרון אינובמד להזרקה 2 מ"ג/מ"ל

inovamed ltd - ondansetron as hydrochloride dihydrate 2 mg / 1 ml - solution for injection - ondansetron - adults:ondansetron inovamed is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. ondansetron inovamed is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:ondansetron inovamed is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.

אונדאנסטרון - פרזניוס ישראל - עברית - Ministry of Health

אונדאנסטרון - פרזניוס

neopharm (israel) 1996 ltd - ondansetron as hydrochloride dihydrate - תמיסה להזרקה - ondansetron as hydrochloride dihydrate 2 mg/ml - ondansetron - ondansetron - adults:for the mangement of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.for the prevention and treatment of post-operative nausea and vomiting (ponv).paediatric population:for the mangement of chemotherapy-induced nausea and vomiting (cinv) in children aged ? 6 months, and for the prevention and treatment of ponv in children aged ? 2 years.

אודנטרון ישראל - עברית - Ministry of Health

אודנטרון

k.s.kim international (sk- pharma) ltd., israel - ondansetron as hydrochloride dihydrate - תמיסה להזרקה - ondansetron as hydrochloride dihydrate 2 mg/ml - ondansetron - ondansetron - adults: odnatron is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. odnatron is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv).paediatric population: odantron is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.

ציפרוקסין 200 ישראל - עברית - Ministry of Health

ציפרוקסין 200

bayer israel ltd - ciprofloxacin as lactate 0.2 g / 100 ml - solution for infusion - ciprofloxacin - adults:uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens.children: for the treatment of acute pulmonary exacerbation of cystic fibrosis associated with pseudomonas aeroginosa infections in pediatric patients aged 5-17 years.

פרזיסטה 75 מג ישראל - עברית - Ministry of Health

פרזיסטה 75 מג

j-c health care ltd - darunavir as ethanolate - טבליות מצופות פילם - darunavir as ethanolate 75 mg - darunavir - darunavir - adult patients : prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv -1) infection. this indication is based on analyses of plasma hiv rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment - naive and treatment -experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment -experienced adult patients .pediatric patients :prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of hiv in pediatric patients 6 years of age and older. this indication is based on week 24 analyses of plasma hiv rna levels and cd4+ cell counts from an open-label phase 2 trial in antiretroviral treatment -experienced pediatric patients 6 to < 18 years of age. in treatment-experienced adult and pediatric the following points should be considered when ini

פרזיסטה 150 מג ישראל - עברית - Ministry of Health

פרזיסטה 150 מג

j-c health care ltd - darunavir as ethanolate - טבליות מצופות פילם - darunavir as ethanolate 150 mg - darunavir - darunavir - adult patients : prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv -1) infection. this indication is based on analyses of plasma hiv rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment - naive and treatment -experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment -experienced adult patients .pediatric patients :prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of hiv in pediatric patients 6 years of age and older. this indication is based on week 24 analyses of plasma hiv rna levels and cd4+ cell counts from an open-label phase 2 trial in antiretroviral treatment -experienced pediatric patients 6 to < 18 years of age. in treatment-experienced adult and pediatric the following points should be considered when ini

רמיקד ישראל - עברית - Ministry of Health

רמיקד

j-c health care ltd - infliximab 100 mg/vial - powder for concentrate for infusion - infliximab - - adult :crohn's disease: treatment of severe active crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. treatment of fistulising crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. -paediatric crohn's disease: remicade is indicated for: treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. remicade has been studied only in combination with conventional immunosuppressive therapy -ankylosing spondylitis: remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional ther